BlackRock Investment Management’s Galectin Therapeutics GALT Stock Holding History

BlackRock Investment Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5K	Hold	4,837	–	–	﹤0.01%	3762
2016 Q3	$5K	Hold	4,837	–	–	﹤0.01%	3775
2016 Q2	$7K	Buy	4,837 +1,358	+39%	+$1.99K	﹤0.01%	3759
2016 Q1	$5K	Hold	3,479	–	–	﹤0.01%	3813
2015 Q4	$6K	Buy	3,479 +383	+12%	+$877	﹤0.01%	3822
2015 Q3	$7K	Hold	3,096	–	–	﹤0.01%	3815
2015 Q2	$8K	Sell	3,096 -51,129	-94%	-$154K	﹤0.01%	3806
2015 Q1	$182K	Buy	54,225 +530	+1%	+$1.89K	﹤0.01%	3235
2014 Q4	$186K	Buy	53,695 +282	+0.5%	+$1.25K	﹤0.01%	3260
2014 Q3	$269K	Buy	53,413 +1,539	+3%	+$12K	﹤0.01%	3199
2014 Q2	$716K	Buy	+51,874	New	+$646K	﹤0.01%	2838

Other funds holding GALT

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's GALT Position: Q4 2016 in Review

BlackRock Investment Management held its Galectin Therapeutics (GALT) position steady in Q4 2016 at 4,837 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

BlackRock Investment Management first reported a position in GALT in Q2 2014 and has held it in 11 quarters since. The position peaked at $716K in Q2 2014. 43 funds tracked by Wall St. Rank hold GALT as of Q4 2016.

BlackRock Investment Management held 4,837 shares of Galectin Therapeutics worth $5K as of Q4 2016.
BlackRock Investment Management left its Galectin Therapeutics share count unchanged in Q4 2016.
Galectin Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3762 holding.
BlackRock Investment Management first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Galectin Therapeutics position peaked at $716K in Q2 2014.
43 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.